Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus intercalated EGFR-TKI vs TKI alone in EGFR-mutant NSCLC
NCT02031601Phase 4Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2014
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of gefitinib, erlotinib, icotinib in non-small cell lung cancer (NSCLC), sponsored by Qilu Hospital of Shandong University. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02031601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031601.